Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

PURPOSE: In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation. The objective of this study was to eval...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Chemother Pharmacol
Päätekijät: Imai, Hisao, Kuwako, Tomohito, Kaira, Kyoichi, Masuda, Tomomi, Miura, Yosuke, Seki, Kaori, Sakurai, Reiko, Utsugi, Mitsuyoshi, Shimizu, Kimihiro, Sunaga, Noriaki, Tomizawa, Yoshio, Ishihara, Shinichi, Ishizuka, Takao, Mogi, Akira, Hisada, Takeshi, Minato, Koichi, Takise, Atsushi, Saito, Ryusei, Yamada, Masanobu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2017
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344961/
https://ncbi.nlm.nih.gov/pubmed/28168310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3232-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
Lataa...

Samankaltaisia teoksia